Conference call to take place on Thursday March 31 at 08:00a.m. Eastern time
AUSTIN, Texas, March 28, 2022 /PRNewswire/ -- VolitionRx Limited
(NYSE AMERICAN: VNRX) ("Volition") today announced it will host a
conference call on Thursday March 31,
08.00a.m. Eastern time to discuss its
financial and operating results for the full fiscal year 2021, in
addition to providing a business update.
Event: VolitionRx Limited Full Fiscal Year 2021 Earnings
and Business Update Conference Call
Date: Thursday, March 31,
2022
Time: 08:00a.m. Eastern
time
U.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13728406
Cameron Reynolds, President and
Chief Executive Officer of Volition, will host the call along with
Terig Hughes, Chief Financial Officer, Dr. Tom Butera, Chief Executive Officer of Volition
Veterinary Diagnostics Development LLC, and Scott Powell, Executive Vice President, Investor
Relations. The call will provide an update on recent developments
and Volition's activities, including details of new and ongoing
clinical trials, important events which have taken place in 2021,
and upcoming milestones.
A live audio webcast of the conference call will also be
available on the investor relations page of Volition's corporate
website at http://ir.volition.com. In addition, a telephone replay
of the call will be available until April
14, 2022. The replay dial-in numbers are 1-844-512-2921
(toll-free) in the U.S. and Canada
and 1-412-317-6671 (toll) internationally. Please use replay pin
number 13728406.
About Volition
Volition is a multi-national epigenetics company that applies
its Nucleosomics™ platform through its subsidiaries to develop
simple, easy to use, cost effective blood tests to help diagnose
and monitor a range of life-altering diseases including some
cancers and diseases associated with NETosis such as sepsis and
COVID-19. Early diagnosis and monitoring have the potential to not
only prolong the life of patients, but also to improve their
quality of life. The tests are based on the science of
Nucleosomics™, which is the practice of identifying and measuring
nucleosomes in the bloodstream or other bodily fluid - an
indication that disease is present. Volition is primarily focused
on human diagnostics and monitoring but also has a subsidiary
focused on animal diagnostics and monitoring.
Volition's research and development activities are centered in
Belgium, with an Innovation
laboratory in California and
additional offices in Texas,
London and Singapore, as the company focuses on bringing
its diagnostic and disease monitoring products to market.
NucleosomicsTM is a trademark of Volition and its
subsidiaries.
For more information about Volition, visit Volition's website
(http://www.volition.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
View original
content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-full-fiscal-year-2021-earnings-conference-call-and-business-update-301512096.html
SOURCE VolitionRx Ltd